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Abstract 
Pharmacist-led initiatives have recently emerged as viable 
strategies for reducing healthcare disparities in diabetes which, as 
the 7th leading cause of death in America, has increasingly become 
a concern for minority groups. Following a literature review that 
focuses on the main factors influencing disparities and pharmacy-
led interventions in diabetes, two strategies are suggested to 
increase the role that pharmacists can play in reducing diabetes 
health care disparity: 1) develop culturally competent 
interventions to increase the ability of pharmacists to educate and 
counsel patients, and 2) increase pharmacists’ prescribing power 
within the health care provider team. Several studies link cost of 
treatment, socio-economic status, and racial differences with long-
term adherence to diabetes medication and demonstrate that 
increased culturally competent pharmacist involvement in patient 
care can decrease costs and increase patient adherence, thereby 
reducing disparity. Pharmacists are critical to the formulation of 
interventions that seek to eliminate health care disparities. 
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Introduction 
 
Healthcare reform is one of the most 
pressing and controversial challenges that the 
American people currently face. Despite the 
variety of viewpoints surrounding this issue, there 
is overwhelming agreement that health care 
disparities are a major source of inefficiency in the 
health care system. The ultimate goal of health 
care reform is the elimination of health care 
disparities across all disease states. In order to 
accomplish this goal, health care providers must 
focus on interventions that yield the greatest 
positive change in the shortest time, which implies 
targeting diseases which are most prevalent within 
the population.  
 
Health care disparities are defined by 
observable inequalities in access to, use of, and 
quality of health care services within a population.  
Inequities in cost, quality and access to care are 
the preferred targets for provider led initiatives to 
eliminate disparity because of the influence that 
health care professionals have over the services 
that they provide. Although the incidence 
(percentage of new cases), prevalence (percentage 
of total cases) and mortality (percentage of deaths) 
of a disease within a specific population over a 
period of time may appear disparate, disparities in 
quality, cost or access to health care may not 
always be the root of the problem. Socioeconomic, 
environmental and genetic factors, among others, 
often account for disparities in specific diseases 
within a population, increasing the complexity 
involved in addressing this issue. 
 
Providers seeking to construct effective 
interventions must consider both the prevalence 
and the significance of health disparities 
associated with specific disease targets.  Because 
of the limited resources allocated for health 
disparity elimination, focusing on such diseases as 
diabetes, asthma, or hypertension, is necessary in 
order to achieve swift, significant success. 
Diabetes deserves special consideration in 
Louisiana, where both the prevalence of the 
disease is high and health care disparities are 
significant. 
 
We are proposing two interventions aimed 
at reducing health care disparities associated with 
diabetes: 1) develop culturally competent 
interventions to increase the ability of pharmacists 
to educate and counsel patients, and 2) increase 
pharmacists’ prescribing power within the health 
care provider team. First, we begin by 
demonstrating that diabetes is an appropriate 
target for interventions that aim to reduce health 
disparity. Next, we identify factors that influence 
health care disparities associated with adherence 
to diabetes treatment. Third, we present the two 
proposed interventions to decrease disparities in 
diabetes and, finally, we discuss the benefits and 
barriers of increasing pharmacist prescribing 
power.     
 
Diabetes: A Target in Health Disparities  
 
 Diabetes is a broad classification used to 
categorize a group of lifelong chronic diseases. 
The most common type, Diabetes mellitus, is a 
disease in which the blood contains high levels of 
glucose (high blood sugar or hyperglycemia), 
either because the body does not produce enough 
insulin (type 1) or because cells do not respond to 
the insulin that is produced (type 2). The clinical 
implications of this pathology are far reaching. 
The Centers for Disease Control and Prevention 
(CDC) named diabetes as the foremost cause of 
renal failure, appendage amputation not associated 
with trauma, and new cases of adult onset 
blindness (2011). Additionally, diabetes is a major 
contributor to the incidence of heart disease and 
stroke, and ranked 7th in the top 10 causes of death 
in America (CDC, 2011).  
 
Because type 1 diabetes is an autoimmune 
disease with genetic origins, health disparities  
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associated with this disease are caused by factors 
other than cost, quality or access to health care 
services. Type 2 diabetes, in contrast, is an 
acquired disease with risk factors including 
obesity, inactive lifestyle, and unhealthy 
nutritional habits. The impact of type 2 diabetes is 
both preventable and reversible if diagnosed and 
treated promptly. According to the CDC (2011), 
diabetes mellitus type 2 represents 90-95% of 
diagnosed cases. These characteristics of diabetes 
mellitus type 2 make this disease an ideal focal 
point for interventions that seek to reduce health 
care disparities. As a result, this paper is 
exclusively focused on health care disparities 
associated with diabetes mellitus type 2, formerly 
called non-insulin-dependent diabetes mellitus 
(NIDDM), and will be referred to here as 
“diabetes.” 
 
Many initiatives address the increasing 
problems associated with diabetes disparity. 
Healthy People 2020 (HP 2020), sponsored by the 
U.S. Department of Health and Human Services, 
has undertaken the task of prioritizing goals with 
specific benchmarks for many diseases that are of 
particular concern to the American population. 
The stated intent of HP 2020 is to improve the 
health of all Americans, and not only addresses 
disparity directly, but also emphasizes the 
importance of patient education, compliance with 
diagnostic testing for diabetes and co-morbid 
diseases, engaging in healthy eating habits and the 
need for positive patient outcomes. The efficiency 
of any initiative in reducing health care disparities 
or disease prevalence can only be determined by 
measuring the outcomes of that initiative against a 
standard. The provision of these standards by HP 
2020 has given health care providers the ability to 
implement successful initiatives that can both 
reduce the prevalence of diabetes and reduce 
health care disparities associated with the disease. 
 
Disparities in diabetes in Louisiana 
According to the Louisiana Department of 
Health Diabetes Report (McCoy et al., 2010), 
7.8% of the total US population and 10.1% of the 
Louisiana population had been diagnosed with 
diabetes in 2007. Healthy People 2020 states that 
nationally, African Americans are 1.7 times more 
likely to be diagnosed with diabetes than non-
Hispanic whites (DHHS, 2010). In Louisiana, 
diabetes prevalence was 13.6% for African 
Americans and 8.8% for Caucasians (McCoy et 
al., 2010).  
 
In addition to racial or ethnic disparity in 
diabetes prevalence, the Louisiana Diabetes 
Report describes socio-economic inequities stating 
that individuals earning less than $25,000 
(accounting for 54.8% of the sample population in 
2007) experienced 15.9% diabetes prevalence 
(McCoy et al., 2010). This figure is significantly 
higher than both the Louisiana and national 
average. Interpretation of the fiscal data associated 
with diabetes is particularly revealing because of 
the three factors that influence healthcare disparity 
(cost, quality and access), cost is the easiest to 
measure. In Louisiana, the cost of diabetes-related 
expenditures was $6,235 per patient for white 
males compared to $8,198 for African-American 
males (McCoy et al., 2010). These statistics paint 
the picture of a disease that is highly prevalent 
within the general population, has a greatly 
increased prevalence amongst minority groups, 
and imposes a heavier burden of treatment on 
minority patients with regard to cost and access to 
quality care. These attributes indicate that a 
reduction in diabetes healthcare disparity will 
result in a significant reduction in diabetes 
prevalence within the general population.  
 
Factors Influencing Adherence to 
Diabetes Treatment 
 
A literature review of factors associated 
with diabetes health care disparity found that the 
most relevant studies focused on the impact of two 
main factors contributing to disparities in 
adherence to treatment: 1) racial and ethnic 
differences, and 2) socioeconomic status 
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Impact of race and ethnicity in adherence 
to treatment 
Adherence to treatment is a major 
challenge to eliminating disparity. A retrospective 
cohort study (Trinacty et al,2009) looked at racial 
disparity in adherence to long term diabetes drug 
regimens within the Boston area. The study 
accounted for accessibility and quality of care by 
using only those patients enrolled in a Health 
Maintenance Organization (HMO) that offered 
prescription coverage. Analyzing 10 years of 
prescription records along with data from clinical 
and pharmacy claims, the study demonstrates both 
long term and short term differences in adherence 
between races. Specifically, the study analyzed 
patient information with regard to prescriptions 
written and prescriptions filled for oral diabetes 
medication. The study ensured equal access to 
medication by considering 1,906 patients that had 
the same type of prescription coverage and 
assessed long term adherence by calculating the 
monthly average rate of adherence.  
 
Interpretation of the data showed 
differences in adherence between races to varying 
degrees throughout the 24 month follow up, but 
the African American group consistently 
demonstrated higher rates of treatment cessation. 
By the end of the follow up assessment over half 
of the African American group had discontinued 
therapy for 60 days or more whereas only 44% of 
the Caucasian group had. This study shows that 
racial differences in compliance to a long term 
drug regimen for oral diabetes medication are 
significant, with African American patients being 
more likely to cease treatment than Caucasian 
patients. This study confirms that given equal 
access to diabetes drug treatment, there is a link 
between race and adherence to long term drug 
regimens.  
 
Impact of low socio-economic status in 
adherence to treatment 
Two studies (LaVeist et al., 2009 and the 
Chernew et al., 2008) analyzed statistically 
significant relations between race/ethnicity 
income, and adherence. Both studies concluded 
that income plays an important role in explaining 
racial/ethnic disparities in diabetes and that 
reducing the cost of medication for low-income 
patients can greatly contribute to reducing health 
disparities.     
 
LaViest et al. (2009) demonstrated the 
effect income has on patient health outcomes by 
comparing two surveys.  The first, Exploring 
Health Disparities in Integrated Communities-
Southwest Baltimore (EHDIC-SWB), was a 2003 
cross sectional study with 1489 participants of 
similar race and low economic status (LaVeist et 
al, 2008). The second survey considered was the 
2003 National Health Interview Survey (NHIS) 
conducted by the US Census Bureau with 29,372 
participants who exhibited significant racial 
disparity with more African-American participants 
earning less than $10,000 a year than Caucasian. 
The results showed that the NHIS ratio of diabetes 
prevalence for African Americans compared to 
Caucasians was 1.57 while the EHDIC-SWB 
survey ratio was only 1.03. By comparing the 
NHIS survey with the EHDIC-SWB survey, the 
authors demonstrated that socio-economic 
inequality is linked with a racially disparate 
diabetes distribution and that a reduction in socio-
economic inequality coincides with a reduction in 
racial/ethnic disparity. This analysis confirms that 
racial/ethnic disparity in diabetes is associated 
with socio-economic disparity. 
 
Chernew et al. (2008) assessed socio-
economic disparities in diabetes treatment using a 
large employer-based insurance company database 
(6 million workers) from 2002 to 2004. The 
authors considered diabetes and congestive heart 
failure and analyzed adherence to medication 
regimens and mean income by zip code as stated 
in the 2000 census. The study showed a 1.08 ratio 
of adherence to diabetes medication from high 
income to low income. The authors compared 
income by assessing four distinct income brackets. 
4
XULAneXUS, Vol. 9 [2011], Iss. 2, Art. 2
https://digitalcommons.xula.edu/xulanexus/vol9/iss2/2
! 
XULAneXUS: Xavier University of Louisiana’s Undergraduate Research Journal 
Special Relationships  11 Pharmacists Frontline 
The lowest income group earned less than $30,000 
whereas the highest income group earned more 
than $62,000. In the diabetes group, the highest 
income bracket was 20% more compliant to drug 
regimens than the lowest income bracket. The 
authors concluded the study by proposing a co-pay 
relief intervention in order to increase adherence 
amongst those patients who have lower incomes. 
This study confirms that cost is a major 
contributor to socio-economic health care 
disparity.  
 
Interventions to Decrease Disparities  
in Diabetes 
 
A literature review of effective prevention 
techniques found that the most relevant studies 
focused on the impact of two main initiatives to 
decrease disparities: 1) implementation of 
culturally-competent interventions involving 
pharmacists counseling, and 2) increase of 
pharmacist’s prescribing power. Results of these 
studies confirm the important impact that 
empowering the pharmacist to provide expanded 
culturally competent services within a primary 
care team can have on increasing patient 
adherence and decreasing cost of treatment, and, 
as a result, on decreasing health disparities.  
 
Impact of culturally-competent 
interventions on reducing disparities 
A systematic literature review of 
interventions published between 1985 and 2006 
(Peek, Cargill, and Huang, 2008), assessed the 
effects of education and counseling on diabetes 
disparity. This review compared 48 reports on 43 
studies, two thirds of which were controlled. The 
authors classified the interventions into three 
categories: patient, provider, and system-wide 
interventions. All of the patient interventions 
involved patient education programs which 
focused on diet, exercise and self-management 
and were intended to increase adherence to 
recommended lifestyle modifications or self-
assessment regimens including blood glucose 
testing. Provider-based interventions sought to 
improve patient outcomes by offering physician 
education and alert systems. The system-wide 
interventions utilized healthcare providers other 
than physicians, including registered nurses and 
pharmacists who offered increased clinical and 
medication management services, respectively, in 
order to reduce diabetes disparity.  
 
Further division of the interventions 
differentiated those that were culturally tailored 
from those that were generally applied to all 
patients. Culturally tailored interventions 
attempted to consider the culture and individual 
characteristics of patients in order to most 
effectively impact patient adherence and improve 
patient outcomes.  Although the patient 
interventions considered to be culturally sensitive 
did not consistently result in a reduction in target 
laboratory values, one-on-one consultation and 
peer counseling did improve patient health more 
than computer or automated initiatives did. The 
provider-based interventions offered no initiatives 
considered to be culturally ‘tailored’; however, the 
authors did infer that an increase in health care 
provider training for treatment of diabetes would 
lead to increased access to specialized diabetes 
care for minorities, which has the potential to 
reduce health care disparity in diabetes. Within the 
health system-wide intervention group two studies 
assessed pharmacist-led medication management 
and education, which resulted in lower HbA1c 
values, increased patient understanding of the 
disease and an increase in overall satisfaction with 
the health services provided. The study concluded 
that patient, provider, and system interventions 
can all be effectively employed to reduce health 
care disparity in diabetes. The most effective 
interventions were personalized, accounted for 
cultural differences and utilized the collaborative 
healthcare team model to increase positive patient 
outcomes and satisfaction.  
 
Another study published by Morello 
(2011) analyzed the results of a cross-sectional 
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survey regarding self-adherence and methods 
perceived to be effective at increasing adherence, 
distributed amongst patients and caregivers 
attending the 2005 Taking Control of Your 
Diabetes conference in San Diego.  Response rate 
was 40.5% with 524 total submissions. The 
authors found that three of the factors that most 
positively influenced medication therapy 
compliance involved patient understanding of the 
purpose, goals and complications of drug 
treatment regimens and recommended pharmacist-
led initiatives to educate and counsel patients 
regarding the benefits of drug therapy and 
techniques to increase adherence. This study 
shows that culturally competent education and 
counseling can be effective methods for 
eliminating this particular factor of health care 
disparity.  
 
Impact of pharmacist prescribing power on 
reducing treatment costs 
Dole (2007) explored the benefits of 
adhering to the healthcare team model by 
examining the implications of pharmacist 
prescribing at a pain clinic in New Mexico. 
According to provisions enacted in 1993 under the 
Pharmacist Prescriptive Authority Act, clinical 
pharmacists are allowed to prescribe under the 
supervision and in collaboration with a physician 
in accordance with specified pre-determined 
protocols. Data collected included patient 
assessment of pain, cost savings, revenue 
generation, and adherence to medication safety 
standards. The results showed a significant 
reduction in patient pain and cost with a savings of 
nearly a half a million dollars to the insurance 
companies billed within one year. The revenue 
recorded by the clinic exceeded the salary of the 
pharmacist. Additionally, pharmacist involvement 
facilitated an increase to the efficacy of the triage 
process by eliminating the necessity of physicians 
seeing patients who required only medication 
management. This allowed the clinic to maintain 
adequate safety standards. Although this study 
does not address diabetes specifically, the 
conclusions may be applied to those disease states, 
like diabetes, that are both chronic and require 
ongoing medication therapy management. 
 
Two interventions reported separately by 
Rodgers and colleagues (1999) and Walker & 
Mathers (2002) described the effects of both 
increasing pharmacist prescribing power and of 
the primary care group approach to health care on 
prescribing costs. Although these interventions did 
not address disparity directly, the lowering of 
prescribing costs assessed by these interventions 
can be applied to strategies that reduce diabetes 
health care disparity by reducing financial barriers 
to healthcare. The first intervention in Doncaster, 
England (Rogers et al., 1999) assessed the effects 
of a pharmacist intervention on prescribing costs 
and involved eight medical practices where 
pharmacists assisted by modifying drug regimens 
and offering patient counseling and education. The 
study assessed prescribing data, accounted for 
variance within the populations of the practices 
and noted significant differences between the 
control and test groups. The authors concluded 
that the intervention diminished enough of the 
prescribing costs to pay the pharmacists for their 
services.  
 
The second intervention, a comparison 
study, in South Derbyshire, England (Walker & 
Mathers, 2002), included nine practices that had 
enacted a primary care group initiative in which a 
pharmaceutical advisor was employed to consult, 
provide feedback, and make recommendations. 
The authors assessed prescribing data regarding 
cost and compared the results to a control group. 
Test group expenditures dropped below the 
control group’s expenditures within one month of 
employing the initiative. This study demonstrates 
how collaborative prescribing by professionally 
diverse members of a health care team can lower 
prescribing costs. Together, these studies show 
that increasing the role of the pharmacist within 
the health care team can effectively reduce 
prescribing costs. This will have the greatest effect 
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on disparity for those diseases like diabetes, which 
are most prevalent and which require the most 
drug intensive treatment. 
 
Barriers to and Benefits of Pharmacists 
Prescribing Power  
 
California, Florida, New Mexico, 
Washington and health services provided by the 
federal government including the Veterans Health 
Administration have pioneered the way for 
increasing the role of the pharmacists within the 
health care team. Florida was one of the first states 
to enact any kind of provision for pharmacist 
prescribing giving pharmacists the “outright 
statutory authority” to “independently” prescribe a 
limited list of drugs.  
 
Doering (2007) reviewed the history of the 
Florida statue along with some of the pitfalls and 
benefits of the law. The author sees a number of 
problems with increasing pharmacist prescriptive 
authority which echoes many of the objections 
that opponents to pharmacist prescribing have 
raised. The more important objection is patient 
safety and the potential for misdiagnosis. 
Pharmacists lack extensive diagnostic training and 
should not attempt to expand their scope of 
practice beyond their education. Rather, the focus 
of the pharmacist as a patient care provider should 
be on the management of patient medication 
regimens and the provision of patient education. 
Doering , in spite of his misgivings, conceded that 
pharmacist prescribing can lead to a decrease in 
cost and an increase in patient satisfaction. As 
long as the lessons learned from the Florida model 
can be incorporated into interventions that 
increase the role of the pharmacist within the 
health care team, cost can be reduced without 
sacrificing patient safety.  These initiatives will 
provide the most useful information about the cost 
benefits, safety and efficacy of pharmacist 
prescribing which may assist the rest of the nation 
in adopting similar policies. 
 
In order to implement a policy that 
increases the pharmacist’s power to treat diabetes 
and educate patients, three distinct phases would 
have to occur. The first is legislative. In his 
retrospective analysis of Florida’s prescribing 
laws, Doering (2007) describes the process by 
which prescriptive authority policy is constructed 
and asserts that this process occurs exclusively at 
the state level. Policy regarding pharmacist 
prescriptive authority throughout American 
history has swung with public sentiment on a 
pendulum between two opposing social values: 
safety and accessibility. Over the last 40 years, as 
public sentiment has shifted away from safety and 
regulation in favor of increased accessibility, more 
and more states have drafted legislation that 
expands the scope of pharmacist prescriptive 
authority. The first states to enact these policies, 
however, did not have access to the extensive 
body of data that is available for policy makers 
today. The assessment of the initiatives enacted by 
these progressive states is critical to the discussion 
of expanding pharmacists’ prescriptive authority 
in states that have not already enacted similar 
policies. Support for these initiatives will only 
come from lawmakers of states more apprehensive 
to increasing the scope of pharmacy practice after 
both the safety and efficacy of pharmacist 
prescribing is confirmed. Although this data 
continues to accumulate as more states implement 
and assess the outcomes of these initiatives, many 
more studies are needed in order to demonstrate a 
positive impact on diabetes and diabetes-related 
illnesses, particularly within minority 
communities. 
 
 Once the political road has been paved, 
pharmacists would have to prepare themselves for 
an increase in responsibilities. A certification 
process would need to be enacted. Shane-
McWhorter (2005) wrote a recommendation for 
the scope of pharmaceutical practice which 
specifically describes the role pharmacists play as 
diabetes educators. This recommendation 
emphasizes the need for pharmacists to receive 
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certified, ongoing, disease-specific education in 
order to educate their patients.  Not only should 
pharmacists be subjected to intensive education 
regarding all aspects of the disease, but they 
should also be educated on how to relay that 
information effectively to their patients. Both of 
these educational requirements would have to be 
above and beyond the standard pharmacy 
education and would most certainly require 
ongoing re-certification. 
 
The third phase of these initiatives would 
involve corporate restructuring. As local 
pharmacies begin to offer expanded services to 
their patients, the companies behind these 
pharmacies would have to devise new staffing and 
billing solutions. An analysis of the ways in which 
pharmacists have contributed to diabetes care in 
America by Armour et al. (2009) concluded that 
despite the significant reduction in costs 
associated with increasing the role of the 
pharmacist in patient care and education, the 
process by which pharmacists receive 
compensation for these services is often 
inefficient. Additionally, the goal of these 
initiatives is not to eliminate physician 
participation, but to utilize the untapped resources 
that pharmacists are able to offer. The health care 
team model functions most efficiently when power 
is disseminated amongst all members. In order to 
maintain the structure of the health care team 
model, pharmacy corporations would have to 
construct an appropriate network of physicians 
and other health care providers into which the 
expanded role of the pharmacist must be 
integrated. The pharmacist must be provided with 
access to a health care team for consultation in 
order to maximize positive patient outcomes. 
 
Increasing the power of pharmacists to 
treat diabetes and educate patients will have a 
bilateral effect on the disease by reducing both 
disparity and prevalence. These initiatives will 
have the greatest positive effects in areas like 
Louisiana that have high diabetes prevalence and 
disparity. Healthy People 2020 suggested that the 
increasing prevalence of diabetes may cause 
dwindling attention and resources available to 
treat the disease. The lack of resources is most 
hard felt within minority communities. In order to 
stem the tide of diabetes affliction, patients need 
access to affordable health care and education.  
  
One way to increase the number of 
diabetes health care providers while decreasing 
costs is to empower pharmacists to treat patients 
within specific disease states by prescribing and 
managing drug treatment regimens. Increasing the 
role of pharmacists within the framework of the 
health care team has the potential to alleviate 
many of the burdens of inefficiency placed upon 
the health care system by disparity and lack of 
access. Those patients who are least likely to see a 
physician regularly would benefit the most. 
Development and implementation of a drug 
treatment strategy could occur at any number of 
local pharmacies which would drastically increase 
the number of facilities providing these services. 
Additionally, those pharmacists who are 
empowered to treat diabetes will also be in a 
unique position to offer education and counseling 
that is culturally specific to the community that 
they serve. Increasing education has been linked 
with increased adherence, which for diseases with 
long term drug regimens like diabetes, often 
diverges along racial and socio-economic lines. 
   
Conclusion 
 
Because of the high rate of diabetes 
prevalence, eliminating diabetes disparity is a 
critical goal of health care reform in Louisiana. 
Both cost and adherence to treatment are major 
obstacles to achieving equitable access to health 
care for minority groups. Studies described in this 
literature review show that decreasing the cost of 
diabetes treatment while offering individual 
patients comprehensive, culturally targeted 
education will result in a decrease in health care 
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disparities with regard to both financial 
accessibility and adherence to treatment.  
 
Provider-led interventions are crucial to 
the movement to eliminate diabetes health care 
disparity and can be of great benefit to 
communities that are both racial/ethnic minorities 
and those of lower income; these are the 
communities most in need of relief in Louisiana. 
Pharmacists have begun to play a front line role in 
disparity elimination and have the potential to 
significantly reduce many of the factors that 
contribute to diabetes disparity. Pharmacist-led 
interventions conducted by empowered 
pharmacists capable of taking on more 
responsibilities within the primary care team and 
offering effective personalized patient counseling 
and education, can reduce health care disparity in 
diabetes treatment by decreasing prescribing costs 
and making specialized diabetes care more 
accessible to lower income and minority patients.  
 
Limitations and Recommendations  
 
The greatest challenge to an intervention 
that seeks to increase pharmacist influence is the 
construction of an infrastructure that can 
accommodate the expansion of the pharmacist’s 
role while maintaining the safety and efficacy of 
treatment. Accountability of pharmacists to a 
health care team would have to be established 
before lawmakers and accrediting organizations 
could stand behind any initiative that expands 
prescribing power. Concentration of prescribing 
and dispensing powers is commonly seen as a 
safety concern. A network of health care providers 
must be available for pharmacists to consult with 
regarding course of treatment for patients in order 
to maintain accountability. Recent advances in 
communication technology are making the 
possibility of such a network an increasing reality.  
Cost is a challenge to the initiative to 
provide pharmacists with cultural competence and 
effective counseling training. In addition to the 
training costs, the time required to perform 
consultations represents labor costs. Pharmacies 
would have to staff according to the new demands 
associated with increased consultation and 
develop standards by which they can be 
reciprocated for their services.       
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